相关实验视频
Updated: Jan 10, 2026

08:50
Depletion and Reconstitution of Macrophages in Mice
Published on: August 1, 2012
40.4K
SGLT2 抑制剂的类效应:重点关注巨细胞介导作用
Bing Shu1, Xisha Chen2, Zhonghao Liu1
1The First Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China; School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.
Pharmacological research
|November 24, 2025
概括
-葡萄糖共运输体2 (SGLT2) 抑制剂调节巨细胞,减少炎症并保护多个器官. 这些SGLT2抑制剂显示出超出糖尿病治疗范围的免疫调节剂的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
背景情况:
- -葡萄糖共运输体2 (SGLT2) 抑制剂主要用于2型糖尿病.
- 新出现的证据表明,SGLT2抑制剂具有显著的免疫调节作用,特别是在巨细胞上.
研究的目的:
- 审查SGLT2抑制剂 (dapagliflozin,empagliflozin,canagliflozin) 调节巨细胞极化,代谢重编程和炎症反应的机制.
- 通过巨细胞调节来探索SGLT2抑制剂的多器官保护潜力.
主要方法:
- 文献综述侧重于SGLT2抑制剂对巨细胞表型 (M1/M2) 和炎症通路 (NF-κB,AMPK/mTOR,JAK/STAT) 的影响.
- 对研究SGLT2抑制剂在心血管疾病,损伤,非酒精性脂肪肝疾病和炎症性肠道疾病中的研究分析.
主要成果:
- SGLT2 抑制剂抑制促炎性 M1 巨细胞,并促进抗炎性 M2 表型.
- 这些药物减少细胞因子的释放 (IL-1β,IL-6,TNF-α) 并减轻心血管和病中的炎症和纤维化.
- 在非酒精性脂肪肝病和炎症性肠病中观察到的抗炎作用.
结论:
- SGLT2 抑制剂通过调节巨细胞极化和炎症反应,产生多器官保护作用.
- 这些药物表现出超出其降糖能力的显著免疫调节潜力.
更多相关视频
相关概念视频
Secondary Active Transport
9.2K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.2K
Secondary Active Transport
136.6K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.6K
Glucose Transporters
27.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.1K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
Glucose Absorption Into the Small Intestine
34.8K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
34.8K

